VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $5.00 target price on the stock.

A number of other research firms have also weighed in on VNRX. Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. StockNews.com initiated coverage on VolitionRx in a report on Thursday. They issued a “sell” rating on the stock.

VolitionRx Stock Performance

NYSE VNRX traded down $0.01 during trading on Thursday, hitting $0.55. The stock had a trading volume of 11,446 shares, compared to its average volume of 178,448. The company has a market capitalization of $50.50 million, a PE ratio of -1.51 and a beta of 1.09. The company’s 50-day moving average price is $0.60 and its two-hundred day moving average price is $0.64. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.02.

Institutional Trading of VolitionRx

A number of institutional investors have recently modified their holdings of VNRX. Two Sigma Securities LLC bought a new stake in shares of VolitionRx during the 4th quarter valued at $29,000. Millennium Management LLC bought a new stake in shares of VolitionRx during the 4th quarter valued at $36,000. Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the period. Geode Capital Management LLC lifted its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares during the period. Finally, Lagoda Investment Management L.P. lifted its position in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.